Following adults with primary membranous nephropathy over time to see how they do
Follows adults with primary membranous nephropathy to describe their long-term health outcomes.
Key facts
- Who runs it
- Mario Negri Institute for Pharmacological Research
- Where
- Italy2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- An Outcome Analysis of Primary Membranous Nephropathy
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 29 Nov 2024
- Expected to end
- Jun 2054
- Type of study
- Observational
- Record updated
- 23 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with primary membranous nephropathy and nephrotic syndrome. It follows how their disease goes over time with treatment such as rituximab or other monoclonal antibodies.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Primary membranous nephropathy with nephrotic syndrome (protein in the urine above 3.5 g/24 hours).
- Biomarker or test result
- Proteinuria >3.5 g/24 hours (protein in the urine).
Main reasons for not taking part
- People who cannot legally make their own decisions, fully or partly
- Any reason a person cannot have rituximab or another monoclonal antibody
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Adults (≥18 years old) on the day of signing informed consent
- Diagnosis of primary membranous nephropathy
- Nephrotic syndrome (proteinuria >3.5 g/24 hours)
- Written informed consent to the use of recorded data for research purposes
Who cannot take part
- Any contraindication to treatment with rituximab or other monoclonal antibody
- Legal incapacity or limited legal capacity
This trial is currently available in Italy.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an observational study intended to track the course of the primary membranous nephropathy disease in real-world clinical practice.
Read full original descriptionShow less
The study will primarily assess the long-term outcomes of patients with primary membranous nephropathy in the context of advances in treatment options.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Observational, Longitudinal Study to Describe the Outcome, and Outcome Predictors, of Patients With Primary Membranous Nephropathy, and the Nephrotic Syndrome Treated With Rituximab, or Other Monoclonal Antibodies
- Plain-language title
- Following adults with primary membranous nephropathy over time to see how they doGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 23 March 2026